Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II crossover study of nebulised RPL554 vs salbutamol and placebo in chronic asthma
2014-005615-17Phase 2Completed
- Sponsor
- Verona Pharma
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ensifentrine in asthma (3 arms), sponsored by Verona Pharma. Primary endpoints: Peak FEV1 over 12 hours and Average FEV1 over 12 hours. Started Mar 2015; status: completed.
02
Drugs
ensifentrine
03
Conditions
asthma
Beyond the preview
Go deeper on 2014-005615-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005615-17.